#USA #financial results #Alameda #thrombectomy #Penumbra Inc

Penumbra, Inc. Reports First Quarter 2026 Financial Results

Penumbra, Inc. (NYSE: PEN), recognized as the leading thrombectomy company globally, revealed its financial results for the first quarter ending on March 31, 2026, marking a remarkable trajectory of growth. The company reported total revenues of $374.8 million, showcasing a significant increase of 15.6% in comparison to the same quarter in 2025.

Revenue Breakdown

The revenue growth can be attributed to robust performance across various product lines, notably in the thrombectomy segment which generated $253.9 million, reflecting a 12.1% increase year-over-year. Similarly, the company’s embolization and access revenue experienced a robust boost, totaling $120.8 million, an impressive growth of 23.8% compared to the first quarter of the previous year. This upward trend underscores Penumbra's strong position in the medical technology market, specifically in critical healthcare solutions aimed at managing conditions like ischemic strokes and venous thromboembolism.

Operating Performance and Margin

Penumbra achieved a gross profit margin of 67.6% in the first quarter of 2026, an uptick of 1.0% from the previous year. The operating expenses reached $215.2 million, which includes $22.4 million allocated to research and development (RD) and $192.8 million on sales, general, and administrative (SGA) expenses. Notably, the quarter also incurred $9.4 million in acquisition-related expenses tied to the pending acquisition by Boston Scientific Corporation.

The income from operations stood at $38.2 million, alongside a net income of $32.6 million, representing a strong operational performance amid impending changes within the company due to the acquisition.

Full Year 2026 Financial Outlook

As a result of the ongoing acquisition process, Penumbra will not provide financial guidance for the remainder of 2026, nor will there be a conference call to discuss these financial results. This strategic move is likely meant to streamline operations during a period of significant change.

About Penumbra

Penumbra is dedicated to innovating technologies that address severe medical conditions. Its comprehensive product range, including computer-assisted vacuum thrombectomy (CAVT), aims to enhance the quality of care by facilitating the quick removal of blood clots across various medical scenarios. With a presence in over 100 countries, the company continues to support healthcare providers in improving patient outcomes.

For individuals looking for further information, Penumbra maintains an active online presence through its website and social media channels, offering insights into its products and corporate initiatives.

Forward-Looking Statements

It's essential to recognize that some statements made in the financial report are forward-looking and carry inherent risks and uncertainties. Factors such as the successful completion of the acquisition, regulatory approvals, competition levels, and market dynamics could significantly influence future performance. The company advises stakeholders to consider these factors when evaluating the report and its implications.

In conclusion, Penumbra, Inc. demonstrates resilience and continued growth, strategically positioning itself within the evolving landscape of healthcare technology. Stakeholders will be keenly observing how the company navigates the upcoming challenges and opportunities resulting from acquisition activities and market competition.